Brenipatide (LY3537031): Eli Lilly's monthly dual GIP/GLP-1 agonist
Brenipatide (development code LY3537031) is a dual agonist of the GIP and GLP-1 receptors developed by Eli Lilly. Its distinguishing feature is a prolonged half-life designed for administration monthlyand a unique clinical positioning focused on addiction and psychiatry rather than just weight loss.
What is Brenipatide?
Brenipatide (international nonproprietary name; development codes LY3537031 / LY-3537031) is a research peptide developed by Eli Lilly. It belongs to the class of dual incretin agonists, like tirzepatide, but differs in its pharmacokinetics and development strategy. It simultaneously activates two receptors:
- GLP-1 Receptor (Glucagon-Like Peptide-1) — regulation of appetite, slowing of gastric emptying, stimulation of glucose-dependent insulin secretion
- GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide) — potentiation of the insulinotropic effect, modulation of lipid metabolism in adipose tissue
Where tirzepatide, semaglutide and retatrutide require administration weeklyBrenipatide was engineered to last much longer in the body — hence the objective of an injection once a month.
Brenipatide is administered subcutaneously. Its long duration of action is thought to be based on structural modifications that confer increased resistance to enzymatic degradation (notably the replacement of certain susceptible residues), significantly prolonging its half-life compared to weekly incretins. The complete sequence and exact molecular mass have not been published in detail by the manufacturer.
Mechanism of action: the dual incretin GIP/GLP-1
Co-activation of GLP-1 and GIP receptors produces synergistic effects on satiety, insulin sensitivity and energy expenditure — greater than what a mono-agonist GLP-1 can achieve.
Action on the GLP-1 receptor — appetite and blood sugar
Activation of GLP-1R in the hypothalamus and brainstem induces:
- A reduction in food intake and an increase in satiety signals
- A slowing of gastric emptying
- Glucose-dependent insulin stimulation and postprandial glucagon reduction
Action on the GIP receptor — metabolic potentiation
Activation of GIPR complements the GLP-1 pathway by potentiating the glucose-dependent insulinotropic effect and modulating lipid storage and mobilization in adipocytes. This dual stimulation aims for better glycemic control and greater metabolic efficiency than monoagonists.
A central action on the reward circuits
This is the most original aspect of Brenipatide. GIP/GLP-1 signaling modulates dopaminergic reward pathways in the central nervous system. It is precisely this central action—on the mechanisms of craving and compulsion—that Eli Lilly is exploring for neuropsychiatric and addiction indications, beyond metabolism.
The Brenipatide signature: monthly administration
The extended half-life is not a minor detail: it changes the very nature of the potential use. A monthly rather than weekly injection greatly reduces the burden of adherence — a crucial issue in populations where regular medication intake is difficult (addictions, psychiatric disorders).
In addiction or mood disorders, adherence to weekly treatment is a major obstacle. A long-acting molecule, administered once a month, directly targets this weakness—hence Eli Lilly's choice of these indications for Brenipatide.
A novel clinical approach: addiction and psychiatry
Unlike retatrutide or tirzepatide, which were initially developed for obesity and diabetes, Eli Lilly is primarily targeting the central nervous system with Brenipatide. The clinical program includes, in particular:
- Alcohol use disorder — Phase 3 trials RENEW-ALC-1 and RENEW-ALC-2 (moderate to severe and risky use)
- Opioid use disorder — dedicated clinical study
- Psychiatric disorders — bipolar disorder, smoking cessation and relapse prevention
- Other avenues explored — asthma (phase 2), cardiovascular, hepatic, metabolic disorders and obesity
The RENEW-ALC-1 trial (NCT07219966) is a phase 3, randomized, double-blind, placebo-controlled study planning to enroll approximately 1,100 participants with moderate to severe alcohol use disorder, with a follow-up of approximately 56 weeks. Recruitment began in late 2025.
Brenipatide vs Tirzepatide vs Retatrutide
Positioning Brenipatide among the multi-receptor agonists of incretins clarifies its uniqueness:
| Molecule | Receptor targets | Frequency | Lead indication | Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Weekly | Obesity / Type 2 diabetes | Marketed |
| Tirzepatide | GIP / GLP-1 | Weekly | Obesity / Type 2 diabetes | Marketed |
| Retatrutide | GLP-1 / GIP / Glucagon | Weekly | Obesity | Phase 3 |
| Brenipatide | GIP / GLP-1 | Monthly | Addiction / alcohol | Phase 3 |
Applications in research
In the laboratory, Brenipatide is of interest to several areas of preclinical and basic research:
- Study of GIP/GLP-1 co-signaling and its synergistic metabolic effects
- Models of the modulation of dopaminergic reward circuits (addiction, compulsion)
- Research on long-acting peptides and half-life engineering
- Comparison of double versus triple incretin profiles (vs tirzepatide and retatrutide)
Key points to remember
- Brenipatide (LY3537031) is a dual GIP/GLP-1 agonist developed by Eli Lilly.
- Its signature is a monthly administration, made possible by a greatly extended half-life.
- Its development primarily targets addiction and psychiatry (alcohol, opioids, bipolar disorder, tobacco), through the action of incretins on reward circuits
- Phase 3 trials RENEW-ALC-1 / RENEW-ALC-2 on alcohol use disorder, recruitment began in late 2025
- The exact sequence and molecular mass have not yet been published.
- No phase 3 efficacy results are available to date.
Scientific sources: Brenipatide — Wikipedia · NCT07219966 — RENEW-ALC-1 (Phase 3) · AdisInsight — Brenipatide (Eli Lilly)
📦 Buy Brenipatide in Europe
Available at MyPeptide.eu • Janoshik-certified HPLC 99%+ purity • Batch COA • Discreet delivery in 2 to 5 business days in Europe

